HK1086193A1 - Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4- - Google Patents

Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Info

Publication number
HK1086193A1
HK1086193A1 HK06107310.2A HK06107310A HK1086193A1 HK 1086193 A1 HK1086193 A1 HK 1086193A1 HK 06107310 A HK06107310 A HK 06107310A HK 1086193 A1 HK1086193 A1 HK 1086193A1
Authority
HK
Hong Kong
Prior art keywords
prevention
treatment
breast cancer
hydroxy tamoxifen
tamoxifen
Prior art date
Application number
HK06107310.2A
Other languages
English (en)
Chinese (zh)
Inventor
Dominique Salin-Drouin
Jacques Wepierre
Philippe Rouanet
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of HK1086193A1 publication Critical patent/HK1086193A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK06107310.2A 2003-04-01 2006-06-28 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4- HK1086193A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
HK1086193A1 true HK1086193A1 (en) 2006-09-15

Family

ID=33131847

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06107310.2A HK1086193A1 (en) 2003-04-01 2006-06-28 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-
HK08113909.5A HK1119950A1 (en) 2003-04-01 2006-06-28 Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08113909.5A HK1119950A1 (en) 2003-04-01 2006-06-28 Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Country Status (12)

Country Link
US (2) US7704516B2 (xx)
EP (3) EP1608353B1 (xx)
JP (1) JP5490346B2 (xx)
AU (1) AU2003294973B2 (xx)
CA (1) CA2519980C (xx)
ES (3) ES2483896T3 (xx)
HK (2) HK1086193A1 (xx)
IL (1) IL170807A (xx)
MX (1) MXPA05010597A (xx)
NO (1) NO333805B1 (xx)
NZ (1) NZ542499A (xx)
WO (1) WO2004087123A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296757A1 (en) * 2002-12-18 2004-07-09 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
DK1572178T3 (da) * 2002-12-18 2006-09-11 Besins Int Lab Behandling af mastalgi med 4-hydroxytamoxifen
EP1608353B1 (en) * 2003-04-01 2014-04-30 Besins Healthcare Luxembourg SARL Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
RU2357726C2 (ru) * 2004-03-22 2009-06-10 Лаборатуар Безен Энтернасьональ Лечение и профилактика доброкачественной опухоли груди 4-гидрокситамоксифеном
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
AU2005293712B2 (en) * 2004-10-14 2011-04-21 Besins Healthcare Luxembourg Sarl 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US9459267B2 (en) 2014-05-12 2016-10-04 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
WO2016031342A1 (ja) * 2014-08-27 2016-03-03 東洋紡株式会社 低誘電接着剤組成物
US10278976B2 (en) 2014-12-12 2019-05-07 Mira Dx, Inc. Methods for treating or preventing cancer in a KRAS-variant patient and for diagnosing risk of developing multiple primary breast tumors
EP4029950A1 (en) * 2016-04-29 2022-07-20 Board of Regents, The University of Texas System Targeted measure of transcriptional activity related to hormone receptors
CN116832020A (zh) 2017-09-11 2023-10-03 阿托萨治疗学公司 制备和使用内昔芬的方法
US20210009865A1 (en) 2018-03-07 2021-01-14 Toagosei Co., Ltd. Adhesive composition, and adhesive layer-equipped layered product using same
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (xx) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ATE200978T1 (de) * 1996-03-29 2001-05-15 S W Patentverwertungs Ges M B KOSMETIKUM BZW. KOSMETIKZUSAMMENSETZUNG ZUR GLÄTTUNG UND STRAFFUNG DER HAUT BEI GESTÖRTEM UNTERHAUT-BINDE-FETTGEWEBE, INSBESONDERE BEI DER ßCELLULITEß
JP2001527037A (ja) 1997-12-23 2001-12-25 ヘキサル アーゲー Ｚ−４−ヒドロキシタモキシフェン及びシクロデキストリンを含む混合物及び薬剤学的組成
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
AU778475B2 (en) 1999-12-16 2004-12-09 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
ATE439829T1 (de) * 2001-12-07 2009-09-15 Besins Int Belgique Gel oder lísung enthaltend dihydrotestosterone, deren herstellungsverfahren und verwendung
DK1572178T3 (da) * 2002-12-18 2006-09-11 Besins Int Lab Behandling af mastalgi med 4-hydroxytamoxifen
AU2003296757A1 (en) * 2002-12-18 2004-07-09 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
EP1608353B1 (en) 2003-04-01 2014-04-30 Besins Healthcare Luxembourg SARL Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
NZ542499A (en) 2008-10-31
US20090186944A1 (en) 2009-07-23
NO333805B1 (no) 2013-09-16
JP2006514967A (ja) 2006-05-18
ES2483896T3 (es) 2014-08-08
JP5490346B2 (ja) 2014-05-14
ES2456958T3 (es) 2014-04-24
HK1119950A1 (en) 2009-03-20
CA2519980A1 (en) 2004-10-14
EP1952810B1 (en) 2014-01-08
IL170807A (en) 2014-08-31
EP1608353A1 (en) 2005-12-28
NO20054526L (no) 2005-09-30
US8475814B2 (en) 2013-07-02
AU2003294973B2 (en) 2010-05-13
WO2004087123A1 (en) 2004-10-14
EP1941871B1 (en) 2014-01-08
AU2003294973A1 (en) 2004-10-25
EP1941871A1 (en) 2008-07-09
US7704516B2 (en) 2010-04-27
CA2519980C (en) 2012-04-10
US20050031695A1 (en) 2005-02-10
EP1952810A1 (en) 2008-08-06
EP1608353B1 (en) 2014-04-30
ES2456957T3 (es) 2014-04-24
MXPA05010597A (es) 2006-03-09

Similar Documents

Publication Publication Date Title
HK1086193A1 (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-
EP1872124A4 (en) DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
EP1968607A4 (en) TREATMENT OF CANCER AND OTHER DISEASES
IL166475A0 (en) Improved treatment of cancer with glutamine
EP1667680A4 (en) COMBINED METHODS OF TREATING CANCER
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
EP1663259A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP1565187A4 (en) CANCER TREATMENT METHODS AND RELATED METHODS
EP1816996A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING PLANT EXTRACTS FOR THE TREATMENT OF CANCER
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1812596A4 (en) TREATMENT OF CANCER AND COMPOSITIONS
EP1737472A4 (en) EFFECTIVE TREATMENT OF TUMORS AND CANCER USING TRICIRIBIN AND ASSOCIATED COMPOUNDS
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP1587837A3 (en) Prostate cancer diagnosis and treatment
AU2003296757A8 (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1125038A1 (en) Iontophoresis preparation for treatment of breast cancer and/or mastitis
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1635694A4 (en) PROCESS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF BREAST CANCER
GB0326578D0 (en) Cancer diagnosis and therapy
AU2003293130A8 (en) Methods for identifying risk of breast cancer and treatments thereof
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0329416D0 (en) Treatment of cancer
EP1409734A4 (en) DIAGNOSIS AND TREATMENT OF CANCER
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231216